Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD Accessibility Statement Skip Navigation FDA clearance of the IND enables Eloxx to open U.S. clinical sites for EXPRESS, its global Phase 2 study of exaluren in nonsense-mutation ADPKDEXPRESS will randomize approximately 60 patients 1:1 to exaluren or placebo for 52 weeks, with annualized htTKV growth as the primary endpoint; first patient dosing expected in 3Q 2027 and topline data in 1H 2029FDA pre-IND feedback indicated that a substantial and durable htTKV effect could support Breakthrough…